BioSpace News Archive

VolitionRx Limited, a multi-national epigenetics company, announced the pricing of an underwritten public offering of 13,000,000 shares of its common stock at a public offering price of $1.27 per share.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced the results of a post-hoc, pooled analysis of the Phase 2 AURA-LV (NCT02141672) and Phase 3 AURORA 1 (NCT03021499) studies, which found that LUPKYNIS® with mycophenolate mofetil (MMF) and low-dose steroids resulted in earlier and greater reductions in proteinuria in lupus nephritis (LN) patients with high proteinuria across biopsy classes, races, and ethnicities.

BostonGene today announced that four abstracts have been accepted for poster presentations and two abstracts have been accepted for online publication for the 2023 ASCO Annual Meeting (ASCO), which will be held June 2 – 6, 2023, at McCormick Place Convention Center in Chicago, IL.

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced that it is scheduled to speak at the William Blair 43rd Annual Growth Stock Conference.

Shasqi, Inc. (“Shasqi”), a clinical-stage biotech company, whose mission is to revolutionize cancer treatment with click chemistry, announced today it has entered into a research collaboration with Johnson & Johnson Enterprise Innovation Inc.

Zenith Epigenetics Ltd. (“Zenith” or the “Company”) reports clinical activity and the advancement in development of its BET inhibitor (BETi) ZEN-3694 in patients with NUT carcinoma (NC). NC is a highly aggressive type of squamous cell cancer with very poor prognosis that often forms in the head, neck, or lungs.

The new research study on the Human Liver Models Market Size and Forecast to 2028 by Type (Liver Organoids, Liver-on-a-Chip, 2D Models, 3D Bioprinting, and Others)

According to our new research study on “3D Printing Medical Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Component [Software and Services

During this year’s AAPS National biotechnology conference, Navigate BioPharma Services, Inc. announced the launch of its new multiplex digital PCR assays for comprehensive quantification of multiple chimeric antigen receptor (CAR) T cells, a type of cancer immunotherapy that involves genetically modifying T cells to recognize and destroy certain cancers.

CureScience™ Institute is pleased to announce the publication of “Designing neoantigen cancer vaccines, trials, and outcomes” by Biswas, N., Chakrabarti, S., Padul, V., Jones, L. D., & Ashili, S.